Open Source Drug Discovery offers an alternative to the proprietary system driving new drug development today. The idea has taken a variety of forms over the years, but in essence is an attempt to replace closed, proprietary processes with open, public ones. A new initiative, the COVID-19 MoonShot, seeks to apply similar principles to development of antiviral treatments for COVID-19. This article offers an overview of the effort.
COVID MoonShot Project
The COVID MoonShot Project is an ad hoc group of individuals and institutions working to develop a drug inhibiting the SARS-CoV-2 main protease (Mpro). Participating institutions include:
- Diamond Light Source. The UK national synchrotron science facility.
- London Lab. A research lab located at the Weizmann Institute (Twitter).
- PostEra AI. A Y-Combinator funded medicinal chemistry as a service startup.
Mpro as the Target
MoonShot's focus is the Mpro protease, also known in the older literature as 3CLpro. This enzyme was first characterized by X-ray crystallography in 2003 using the enzyme expressed by SARS-CoV-1. Mpro cleaves a polyprotein chain transcribed from viral RNA at 11 or more sites. The enzyme is thought to exist as a dimer in its active state, with an unobstructed, shallow active site hosting a catalytic Cys-His diad. Mpro is thought to be essential for the virus, but evidence on this point seems fuzzy at best.
More recently, the X-ray crystal structure of SARS-CoV-2 Mpro was determined both alone and bound to peptides 13a, 13b, and 14b. Inhibition of purified recombinant CARS-CoV-2 Mpro by 13b was determined as 670 nM. A functional assay of SARS-CoV-2 activity using 14b was performed (EC50 4-µM). Mouse ADME parameters for both 13a and 13b were determined.
As-yet unpublished results from the Diamond Light Source have yielded X-ray crystal structures for 66 fragments, 44 of which were covalently bound to SARS-CoV-2 Mpro. Data are available in a variety of formats, including PDB and Excel files.
The goal of the COVID MoonShot project is to apply the growing amounts of structural data on Mpro to the development of "effective, easy-to-make anti-COVID drugs."
The Diamond Light Source team has compiled a timeline of its efforts. Recently, a hackathon was announced. The MoonShot group announced the closure of the first wave of structure design submissions. Candidates from this set have been selected, and samples have been requested from supplier Enamine. Results (of unspecified type) are to be posted here.
It's early days for the COVID Moonshot. Even so, I don't recall any project quite like it. If you have a background in or inclination toward molecular design, the project may be worth your time.
Having worked in drug discovery as a medicinal chemist for many years, however, I can't help but thinking about the steps following design and compound synthesis. In vitro assays, probably with recombinant enzyme, will be a vital component of any successful project. For a relatively unexplored target such as SARS-CoV-2 Mpro, in vitro assay throughput could become a bottleneck. It's not clear how the MoonShot will address the problem of in vitro assays, and a request for information I sent by Twitter remains unanswered. That's just the start of the labor and expense. The project is going to need resources in DMPK/ADME, not to mention functional animal models. It will also need an information technology infrastructure, as the limits of simple websites and Twitter already begin to surface. The there's the thorny problem of intellectual property, particularly among participants who also work in industry. These and many other challenges could help shape new models for running drug discovery programs.
Crises have a way of making previously unthinkable leaps into the unknown possible.
The COVID MoonShot is a loose association of institutions and individuals organized around the goal of finding a practical COVID-19 treatment. Current efforts are focused on SARS-CoV-2 Mpro inhibitors, but I suspect that could change as new information emerges. Regardless of your scientific background or skills, the project is worth exploring.